...
ganx-img

Gain Therapeutics Inc, Common Stock

GANX

NMQ

$1.57

+$0.01

(0.64%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$41.38M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
115.99K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.34
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.89 L
$5.33 H
$1.57

About Gain Therapeutics Inc, Common Stock

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGANXSectorS&P500
1-Week Return-5.42%-0.94%-2.6%
1-Month Return-13.74%-5.08%-1.08%
3-Month Return1.29%-10.62%3.45%
6-Month Return21.71%-6.18%8.57%
1-Year Return-41.42%1.98%24.3%
3-Year Return-72.43%-0.93%25.58%
5-Year Return-85.98%33.84%84.07%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue41.30K28.88K164.99K140.11K55.18K[{"date":"2019-12-31","value":25.03,"profit":true},{"date":"2020-12-31","value":17.5,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.92,"profit":true},{"date":"2023-12-31","value":33.44,"profit":true}]
Cost of Revenue-2.26M7.16M64.17K80.38K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":31.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.9,"profit":true},{"date":"2023-12-31","value":1.12,"profit":true}]
Gross Profit41.30K(2.23M)(7.00M)75.94K(25.20K)[{"date":"2019-12-31","value":54.39,"profit":true},{"date":"2020-12-31","value":-2936.95,"profit":false},{"date":"2021-12-31","value":-9216.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-33.19,"profit":false}]
Gross Margin100.00%(7722.46%)(4242.11%)54.20%(45.67%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7722.46,"profit":false},{"date":"2021-12-31","value":-4242.11,"profit":false},{"date":"2022-12-31","value":54.2,"profit":true},{"date":"2023-12-31","value":-45.67,"profit":false}]
Operating Expenses2.14M3.51M13.99M17.92M22.31M[{"date":"2019-12-31","value":9.6,"profit":true},{"date":"2020-12-31","value":15.73,"profit":true},{"date":"2021-12-31","value":62.72,"profit":true},{"date":"2022-12-31","value":80.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(2.10M)(3.48M)(13.83M)(17.78M)(22.25M)[{"date":"2019-12-31","value":-210010900,"profit":false},{"date":"2020-12-31","value":-347944900,"profit":false},{"date":"2021-12-31","value":-1382617300,"profit":false},{"date":"2022-12-31","value":-1777704500,"profit":false},{"date":"2023-12-31","value":-2225313300,"profit":false}]
Total Non-Operating Income/Expense(106.76K)(89.21K)(47.93K)654.64K616.63K[{"date":"2019-12-31","value":-16.31,"profit":false},{"date":"2020-12-31","value":-13.63,"profit":false},{"date":"2021-12-31","value":-7.32,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.19,"profit":true}]
Pre-Tax Income(2.19M)(3.57M)(13.89M)(17.50M)(22.19M)[{"date":"2019-12-31","value":-218633100,"profit":false},{"date":"2020-12-31","value":-357229600,"profit":false},{"date":"2021-12-31","value":-1388659800,"profit":false},{"date":"2022-12-31","value":-1749776200,"profit":false},{"date":"2023-12-31","value":-2218824500,"profit":false}]
Income Taxes7.11K5.39K4.01K92.98K79.28K[{"date":"2019-12-31","value":7.65,"profit":true},{"date":"2020-12-31","value":5.79,"profit":true},{"date":"2021-12-31","value":4.31,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":85.26,"profit":true}]
Income After Taxes(2.19M)(3.58M)(13.89M)(17.59M)(22.27M)[{"date":"2019-12-31","value":-219344500,"profit":false},{"date":"2020-12-31","value":-357768200,"profit":false},{"date":"2021-12-31","value":-1389060600,"profit":false},{"date":"2022-12-31","value":-1759073800,"profit":false},{"date":"2023-12-31","value":-2226752000,"profit":false}]
Income From Continuous Operations(2.19M)(3.58M)(13.89M)(17.59M)(22.22M)[{"date":"2019-12-31","value":-219344500,"profit":false},{"date":"2020-12-31","value":-357768200,"profit":false},{"date":"2021-12-31","value":-1389060600,"profit":false},{"date":"2022-12-31","value":-1759073800,"profit":false},{"date":"2023-12-31","value":-2221801700,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(2.19M)(3.58M)(13.89M)(17.59M)(22.27M)[{"date":"2019-12-31","value":-219344500,"profit":false},{"date":"2020-12-31","value":-357768200,"profit":false},{"date":"2021-12-31","value":-1389060600,"profit":false},{"date":"2022-12-31","value":-1759073800,"profit":false},{"date":"2023-12-31","value":-2226752000,"profit":false}]
EPS (Diluted)-(0.73)(1.51)(1.48)(1.78)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-72.59,"profit":false},{"date":"2021-12-31","value":-151,"profit":false},{"date":"2022-12-31","value":-148,"profit":false},{"date":"2023-12-31","value":-178,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GANX
Cash Ratio 2.62
Current Ratio 2.99

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GANX
ROA (LTM) -72.96%
ROE (LTM) -188.83%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GANX
Debt Ratio Lower is generally better. Negative is bad. 0.38
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.62

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GANX
Trailing PE NM
Forward PE NM
P/S (TTM) 925.92
P/B 4.67
Price/FCF NM
EV/R 138.33
EV/Ebitda NM

FAQs

What is Gain Therapeutics Inc share price today?

Gain Therapeutics Inc (GANX) share price today is $1.57

Can Indians buy Gain Therapeutics Inc shares?

Yes, Indians can buy shares of Gain Therapeutics Inc (GANX) on Vested. To buy Gain Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GANX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Gain Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Gain Therapeutics Inc (GANX) via the Vested app. You can start investing in Gain Therapeutics Inc (GANX) with a minimum investment of $1.

How to invest in Gain Therapeutics Inc shares from India?

You can invest in shares of Gain Therapeutics Inc (GANX) via Vested in three simple steps:

  • Click on Sign Up or Invest in GANX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Gain Therapeutics Inc shares
What is Gain Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Gain Therapeutics Inc (GANX) is $5.33. The 52-week low price of Gain Therapeutics Inc (GANX) is $0.89.

What is Gain Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Gain Therapeutics Inc (GANX) is

What is Gain Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Gain Therapeutics Inc (GANX) is 4.67

What is Gain Therapeutics Inc dividend yield?

The dividend yield of Gain Therapeutics Inc (GANX) is 0.00%

What is the Market Cap of Gain Therapeutics Inc?

The market capitalization of Gain Therapeutics Inc (GANX) is $41.38M

What is Gain Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Gain Therapeutics Inc is GANX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top